Propanc Biopharma declined 19.3% to $1.80 ahead of Friday’s session. Premarket trading volume totaled 438,319 shares at 06:09 EDT, data from StockAnalysis showed.
Company hubNASDAQ:PPCB
Follow the latest Propanc (PPCB) company news, earnings coverage and investor analysis from TechStock².
Premarket snapshot: August 28, 2026, 06:09 EDT · PRP data released August 27, 2026
The premarket quote remains about 68% above Wednesday’s close.
| Claim | Reported result | Stage | What investors still need |
|---|---|---|---|
| Tumor control | >90% mean inhibition | Orthotopic and PDX animal models | Human dose-response evidence |
| Survival | >2.5× median extension | Animal models | Clinical survival data |
| Combination potential | Improved chemotherapy sensitivity | Preclinical | Safety and efficacy in patients |
| Regulatory path | CTA expected in coming months | Preparation | Filed and accepted application |
| Phase 1b | About 40–45 patients planned | Not started | Site activation and enrollment |
| Revenue, March quarter | $0 |
| Quarterly net loss | $6.36M |
| Cash at March 31 | $443,702 |
| Subsequent financing tranche | $500,000 |
| Loss / current market value | 1.25× |
| Analyst coverage | 1 Sell · no target |
Financial figures are the latest disclosed quarterly data, not a current cash balance.
Sources: Propanc Biopharma releases dated August 27 and May 15, 2026; StockAnalysis premarket screen; MarketBeat analyst summary. Figures may change after the regular-session open.
Propanc also reported fewer liver and peritoneal metastases. It said PRP increased sensitivity to gemcitabine/nab-paclitaxel in resistant cells. These are company-reported preclinical findings.
| Cash | $0.44M |
| Nine-month operating cash use | $4.08M |
| Nine-month revenue | $0 |
| Nine-month net loss | $14.29M |
| Going concern | Substantial doubt |
Company filing for the period ended March 31, 2026.
| Signal | Why it matters | Next verification |
|---|---|---|
| Preclinical efficacy | Large reported effect created attention | Independent reproduction and full dataset |
| Regulatory execution | Unlocks first human dosing | Clinical-trial application acceptance |
| Manufacturing | Required for dosing consistency | GMP batch completion and release |
| Financing | No revenue and limited cash | Funding terms, dilution and runway |
| Analyst coverage | No broad consensus located | Institutional initiation or published estimates |
Animal-model success frequently fails to translate into patients. PRP has not established human safety or efficacy. Regulatory delay, manufacturing problems, thin trading liquidity and equity financing could reverse Thursday’s gain quickly.
Sources: Propanc releases dated Aug. 18 and Aug. 27, 2026; Propanc Form 10-Q for March 31, 2026; market data at 11:41 ET.
